| __timestamp | Bausch Health Companies Inc. | Sanofi |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 8565000000 |
| Thursday, January 1, 2015 | 2682700000 | 9496000000 |
| Friday, January 1, 2016 | 2810000000 | 9592000000 |
| Sunday, January 1, 2017 | 2582000000 | 10164000000 |
| Monday, January 1, 2018 | 2473000000 | 9934000000 |
| Tuesday, January 1, 2019 | 2554000000 | 9883000000 |
| Wednesday, January 1, 2020 | 2367000000 | 9390000000 |
| Friday, January 1, 2021 | 2624000000 | 9555000000 |
| Saturday, January 1, 2022 | 2625000000 | 10539000000 |
| Sunday, January 1, 2023 | 2917000000 | 10765000000 |
| Monday, January 1, 2024 | 9183000000 |
Unleashing insights
In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic planning. Sanofi and Bausch Health Companies Inc. offer a fascinating comparison in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Over this period, Sanofi consistently outspent Bausch Health, with an average SG&A expense nearly four times higher. Notably, Sanofi's SG&A expenses peaked in 2023, reaching approximately 10.8 billion, marking a 26% increase from 2014. In contrast, Bausch Health's expenses showed a more modest growth, with a 44% increase over the same period, peaking at around 2.9 billion in 2023. This disparity highlights Sanofi's aggressive market strategies and expansive operations compared to Bausch Health's more conservative approach. As the industry faces new challenges, these spending patterns provide insights into each company's strategic priorities and market positioning.
Novartis AG and Sanofi: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Sanofi or Teva Pharmaceutical Industries Limited
Cost Management Insights: SG&A Expenses for Sanofi and Mesoblast Limited
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Bausch Health Companies Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Bausch Health Companies Inc.
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Bausch Health Companies Inc.
Cytokinetics, Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Bausch Health Companies Inc.
Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Bausch Health Companies Inc. or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Galapagos NV
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.